Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer.

Pollin, Gareth; Lomberk, Gwen A; Mathison, Angela J; Zimmermann, Michael T; Urrutia, Raul.

Afiliação

Pollin G; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Lomberk GA; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Mathison AJ; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Zimmermann MT; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Urrutia R; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

J Gastrointest Oncol ; 15(4): 1996-2001, 2024 Aug 31.

Article em En | MEDLINE | ID: mdl-39279937